Synthesis and Spectral Characterization of Related Substances of Vardenafil, an Erectile Dysfunction Drug

REFERENCES

• Boolell , M. ; Allen , M. J. ; Ballard , S. A. ; Gepi-Attreo , S. ; Muirhead , G. J. ; Naylor , A. M. ; Osrerloh , I. H. ; Gingell , J. C. Sildenafil: An orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction . Int. J. Impot. Res. 1996 , 8 , 47 .
   PubMedGoogle Scholar
• Haning , H. ; Niewohner , U. ; Schenke , T. ; Es-Sayed , M. ; Schmidt , G. ; Lampe , T. ; Bischoff , E. Imidazo[5,1-f][1,2,4]triazin-4(3H)-ones, a new class of potent PDE-5 inhibitors . Bioorg. Med. Chem. Lett. 2002 , 12 , 865 .
   PubMed Web of Science ®Google Scholar
• (a) Niewohner , U. ; Es-Sayed , M. ; Haning , H. ; Schenke , T. ; Schlemmer , K. H. ; Keldenich , J. ; Bischoff , E. ; Perzborn , E. ; Dembowsky , K. ; Serno , P. ; Nowakowski , M. 2- Phenyl substituted imidazotriazinones as phsophodiesterase inhibitors. U.S. Patent 6,362,178, 2002; (b) Sorbera , L. A. ; Martin , L. ; Rabasseda , X. ; Castaner , J. Vardenafil . Drugs Future 2001 , 26 ( 2 ), 141
   Google Scholar
• Jacobson-Kram , D. ; McGovern , T. Toxicological overview of impurities in pharmaceutical products . Adv. Drug Deliv. Rev. 2007 , 59 , 38 .
   PubMed Web of Science ®Google Scholar
• Basak , A. K. ; Raw , A. S. ; Al Hakim , A. H. ; Furness , S. ; Samaan , N. I. ; Grill , D. S. ; Patel , H. B. ; Powers , R. F. ; Yu , L. Pharmaceutical impurities: Regulatory perspective for abbreviated new drug applications . Adv. Drug Deliv. Rev. 2007 , 59 , 64 .
   PubMed Web of Science ®Google Scholar
• Gorog , S. ; Babjak , M. ; Balogh , G. ; Brlik , J. ; Csehi , A. ; Dravecz , F. ; Gazdag , M. ; Horvath , P. ; Lauko , A. ; Varga , K. Drug impurity profiling strategies . Talanta 1997 , 44 , 1517 .
   PubMed Web of Science ®Google Scholar
• Dobo , K. L. ; Greene , K. L. ; Cyr , M. O. ; Caron , S. ; Ku , W. W. The application of structure-based assessment to support safety and chemistry diligence to limit genotoxic impurities in active pharmaceutical ingredients during drug development . Reg. Toxicol. Pharm. 2006 , 44 , 282 .
   PubMed Web of Science ®Google Scholar
• Argentine , M. D. ; Owens , P. K. ; Olsen , B. A. Strategies for the investigation and control of process-related impurities in drug substances . Adv. Drug Deliv. Rev. 2007 , 59 , 12 .
   PubMed Web of Science ®Google Scholar
• International Conference on Harmonisation. ICH Q3A (R2); Impurities in New Drug Substances, Step 4 Version; ICH: Rockville, MD, 2006.
   Google Scholar
• International Conference on Harmonisation. ICH Q3B (R2): Impurities in New Drug Products, Step 4 Version; ICH: Rockville, MD, 2006.
   Google Scholar
• Ku , H.-Y. ; Shon , J.-H. ; Liu , K.-H. ; Shin , J.-G. ; Bae , S. K. Liquid chromatography/tandem mass spectrometry method for the simultaneous determination of vardenafil and its major metabolite, N-desethylvardenafil, in human plasma: Application to a pharmacokinetic study . J. Chromatogr. B 2009 , 877 , 95 .
   PubMed Web of Science ®Google Scholar
• Bischoff , E. Vardenafil preclinical trial data: Potency, pharmacodynamics, pharmacokinetics, and adverse events . Int. J. Impot. Res. 2004 , 16 (Suppl. 1), S34.
   Web of Science ®Google Scholar
• Flores , J. R. ; Nevado , J. J. B. ; Penalo , G. C. Diez , N. M. Development of a micellar electrokinetic capillary chromatography method for the determination of three drugs employed in the erectile dysfunction therapy . J Chromatogr. B 2004 , 811 , 231 .
   PubMed Web of Science ®Google Scholar